The Bull Case For Otsuka Holdings (TSE:4578) Could Change Following Upgraded 2026 Earnings Guidance - Learn Why
- In July 2026, Otsuka Holdings Co., Ltd. raised its consolidated earnings guidance for the first half of 2026, now projecting revenue of ¥1,332,000 million and operating profit of ¥278,000 million, with basic earnings per share guided to ¥407.90.
- The upgrade reflects stronger-than-expected demand for key drugs such as JYNARQUE, ABILIFY MAINTENA, VOYXACT, REXULTI, and LONSURF, a weaker yen boosting overseas revenues, and lower projected research and development spending after discontinuing certain ulotaront indications.
- We’ll now examine how this guidance upgrade, driven by stronger sales of core drugs and lower R&D costs, reshapes Otsuka’s investment narrative.
We've uncovered the 41 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Otsuka Holdings Investment Narrative Recap
To own Otsuka, you need to be comfortable with a company whose story still revolves around a handful of blockbuster CNS and nephrology drugs, while it works to build out newer franchises. The guidance upgrade points to a strong near term earnings catalyst from better sales of JYNARQUE, ABILIFY MAINTENA, VOYXACT, REXULTI, and LONSURF, helped by a weaker yen and lower R&D. The biggest near term risk remains the looming loss of exclusivity on these same drugs and the timing of generic entry.
Against this backdrop, Otsuka’s ongoing share buyback program, announced in February 2026 for up to 7,000,000 shares or ¥50,000 million, matters more. With the company now expecting higher first half profits, this capital return sits directly alongside the upgraded guidance as a key part of the short term story, reinforcing how management is balancing near term cash generation with the longer term need to fund its pipeline beyond today’s core products.
Yet, in contrast to the upbeat guidance, investors should also be aware of the risk that heavy dependence on a few blockbusters could...
Read the full narrative on Otsuka Holdings (it's free!)
Otsuka Holdings’ narrative projects ¥2,791.3 billion revenue and ¥398.3 billion earnings by 2029. This requires 3.5% yearly revenue growth and about a ¥21.8 billion earnings increase from ¥376.5 billion today.
Uncover how Otsuka Holdings' forecasts yield a ¥13025 fair value, a 15% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were already assuming flat revenue near ¥2,532,300 million and earnings falling to about ¥337,700 million, so this guidance surprise may prompt you to rethink how pessimistic that view really is compared with the patent and pricing risks we just discussed.
Explore another fair value estimate on Otsuka Holdings - why the stock might be worth just ¥17961!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Otsuka Holdings research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Otsuka Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Otsuka Holdings' overall financial health at a glance.
No Opportunity In Otsuka Holdings?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- AI is about to change healthcare. These 7 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com